Cilta-Cel Sustains MRD-Negative Responses in Previously Treated Multiple Myeloma.
- Published in:
- OncologyLive, 2024, v. 25, n. 6, p. 60
- By:
- Publication type:
- Article
Works matching IS 23745347 AND DT 2024 AND VI 25 AND IP 6
Results: 15
1
2
Addition of Lifileucel to Advanced Melanoma Arsenal Marks Milestone for TIL Therapy.
- Published in:
- OncologyLive, 2024, v. 25, n. 6, p. 10
- By:
- Publication type:
- Article
3
Liso-Cel Demonstrates Durable Efficacy in Relapsed or Refractory CLL/SLL.
- Published in:
- OncologyLive, 2024, v. 25, n. 6, p. 56
- By:
- Publication type:
- Article
4
Clinicians Turn Their Focus to pMMR Disease Following Immunotherapy's Entrance Into dMMR Endometrial Cancer.
- Published in:
- OncologyLive, 2024, v. 25, n. 6, p. 24
- By:
- Publication type:
- Article
5
ZANUBRUTINIB VS ACALABRUTINIB: Breaking Down the Data With Second-Generation BTK Inhibitors in CLL.
- Published in:
- OncologyLive, 2024, v. 25, n. 6, p. 52
- By:
- Publication type:
- Article
6
The New Frontier With Integrative Oncology: Shooting for the Stars.
- Published in:
- OncologyLive, 2024, v. 25, n. 6, p. 48
- By:
- Publication type:
- Article
7
Why Health Care Providers and Facilities Need to Transition to Value-Based Care.
- Published in:
- OncologyLive, 2024, v. 25, n. 6, p. 41
- By:
- Publication type:
- Article
8
Immunotherapy-Based Approaches Make Waves in Bladder Cancer.
- Published in:
- OncologyLive, 2024, v. 25, n. 6, p. 16
- By:
- Publication type:
- Article
9
QUALITY OVER QUANTITY: What Concierge Medicine Can Offer to Patients With Cancer and Employers.
- Published in:
- OncologyLive, 2024, v. 25, n. 6, p. 40
- By:
- Publication type:
- Article
10
FAK Inhibition Emerges as a Potential Complementary Treatment Pathway.
- Published in:
- OncologyLive, 2024, v. 25, n. 6, p. 31
- By:
- Publication type:
- Article
11
Emavusertib Progresses to Phase 2 Study in AML and MDS.
- Published in:
- OncologyLive, 2024, v. 25, n. 6, p. 34
- By:
- Publication type:
- Article
12
Drug Spotlight.
- Published in:
- OncologyLive, 2024, v. 25, n. 6, p. 11
- Publication type:
- Article
13
FDA Digest.
- Published in:
- OncologyLive, 2024, v. 25, n. 6, p. 8
- Publication type:
- Article
14
The Critical Nature of Decision-Making in the Development of Phase 3 Clinical Trials.
- Published in:
- OncologyLive, 2024, v. 25, n. 6, p. 6
- By:
- Publication type:
- Article
15
Getting Primed for the Next Wave of Updates Across Oncology.
- Published in:
- OncologyLive, 2024, v. 25, n. 6, p. 4
- By:
- Publication type:
- Article